Portfolio: CBC Group and Ensem Therapeutics
CBC Group plans to allocate USD 300m from its latest flagship fund to a biotech incubation platform. Artificial intelligence-enabled drug discovery player Ensem Therapeutics is an example of what it wants to achieve.
The disruptive impact of artificial intelligence (AI) on drug development has been profound. It is increasingly used to accelerate the initial stages of the discovery process – predicting novel targets,...
More on Greater China
Latest News
China's Black Sesame completes Series C with $500m haul
Black Sesame Technologies, a China-based chipmaker specializing in autonomous driving applications, has closed a Series C extension led by SummitView Capital. This brings the size of the overall round to USD 500m.
J-Star invests Japanese courier business
Japanese lower middle-market private equity firm J-Star has made an investment of undisclosed size in air cargo transportation and courier services provider Score Japan Holdings.
Gaorong, Tsing Song back China CDMO IntellectiveBio
Gaorong Capital and Tsing Song Capital have led a CNY 500m (USD 74m) Series C for IntellectiveBio, a China-based contract development and manufacturing organisation (CDMO).
Morningside joins round for China's Epigenic Therapeutics
Morningside Venture Capital has teamed up with Kingray Capital, Trinity Innovation Fund, TigerYeah Capital, and FountainBridge Capital to provide USD 20m in angel and pre-Series A funding for Epigenic Therapeutics, a China-based gene editing specialist.